X

Drug Profile

Research programme: muscarinic M1 receptor agonists - TorreyPines Therapeutics

Alternative Names: NGX 292

Latest Information Update: 22 Oct 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Life Science Research Israel
Developer TorreyPines Therapeutics Inc
Class Small molecules
Mechanism of Action Muscarinic M1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Alzheimer's disease

Most Recent Events

22 Oct 2008 Discontinued - Preclinical for Alzheimer's disease in USA (unspecified route)
04 Oct 2006 TorreyPines Therapeutics has merged with Axonyx to form TorreyPines Therapeutics, Inc.
10 Jan 2006 Preclinical trials in Alzheimer's disease in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com